Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

BACKGROUND: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. More than half the patients had an adverse event of grade 3 or 4.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Glofitamab is a bispecific antibody that recruits T cells to tumor cells.
• 2 METHODS: In the phase 2 part of a phase 1-2 study, we enrolled patients with relapsed or refractory DLBCL who had received at least two lines of therapy previously.
• 3 Patients received pretreatment with obinutuzumab to mitigate cytokine release syndrome, followed by fixed-duration glofitamab monotherapy (12 cycles total).

This work deepens our understanding of the fundamental laws governing the universe, from subatomic particles to cosmic structures.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: